Form 4: Metsera, Inc. Executive Steven Marso Granted Stock Options

Steven Marso, Chief Medical Officer of Metsera, Inc., was granted stock options for 120,000 shares of common stock on May 20, 2025, according to a Form 4 filing.

Summary

• Steven Marso, the Chief Medical Officer of Metsera, Inc., filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Marso on May 20, 2025.
• These options allow him to purchase 120,000 shares of Metsera's common stock at an exercise price of $29.25 per share.
• The options vest in 48 equal monthly installments, starting from the grant date, and will be fully vested on the fourth anniversary, contingent upon continued service.
• Marso also granted a power of attorney to Christopher Whitten, BernardChristopher Visioli, and Matthew Lang to handle SEC filings related to Metsera securities.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service and contribution from the Chief Medical Officer.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options to incentivize their executives.
• The vesting schedule of 4 years is also a common industry practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to contribute to the company's long-term success.
• Employees may see this as a positive sign of investment in leadership.

Key Dates

Keywords

Form 4, stock options, Metsera, Steven Marso, Chief Medical Officer, beneficial ownership, SEC, MTSR